PRCT Stock Forecast & Price Target

PROCEPT BioRobotics is supported by strong underlying commercial momentum, as HYDROS accounts delivered procedures more than 35% higher than legacy AquaBeam accounts in 3Q26, signaling better utilization and a strengthening installed base. The replacement program is also outperforming expectations, with 20 replacement systems placed in the quarter and 36 YTD, while roughly 70% of systems were launched by the dedicated team, which management expects can cover 100% by year-end. New-system ASP remained healthy at about $495k, handpiece sales returned above a 1:1 ratio with procedures, and international revenue rose 32% y/y, all of which point to improving revenue quality and a path to better profitability.

PROCEPT BioRobotics is facing a deteriorating fundamental backdrop as 3Q26 sales of $98.3 million missed consensus and new-system placements fell to 42, well below expectations, while U.S. procedure utilization remained down about 9% year over year. The company’s growth algorithm now depends on an aggressive 4Q26 ramp to reach its full-year target, but persistent AquaBeam weakness, capital budget pressure, and the risk of pricing competition make that step-up look increasingly difficult. Although gross margin held at 66.3%, adjusted EBITDA margin of (10.0%) lagged consensus and the business still relies on sustained procedure growth to justify valuation, leaving limited confidence in a durable reacceleration.